Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
To clean your smart transmitter, wipe it down with a water dampened cloth. Reuse after drying completely.
When traveling, your smart transmitter and sensor are safe to go through airport security without removing them. You may inform security that you have an implanted medical device.
Your smart transmitter will automatically sync to your smartphone’s current time and date when time zones are changed. You should allow for automatic syncing or manually change the time zone (not the time) if needed.
The Eversense® E3 CGM System is safe for use on U.S. commercial airlines. The Eversense® E3 Smart Transmitter is a Medical Portable Electronic Device (M-PED) with emission levels that meet FAA mandates for use in all modes while in flight. (Reference FAA Advisory, Circular #21-16G, dated 6.22.2011.) To use, turn your mobile device’s Bluetooth® feature on after you have put your mobile device in airplane mode. For flights outside the US, follow local security regulations for use of medical devices in flight.
The system will re-enter Initialization Phase for any one of the following reasons:
- Calibration period has expired without you having entered a fingerstick test value.
- 3 or more blood glucose readings are significantly different than the current sensor glucose readings.
- Y our smart transmitter has not been charged within 16 hours of the empty battery alert.
- If you manually change the time on your mobile device your smart transmitter will sync and reinitialize to your mobile device.
- A new transmitter has been linked to your existing sensor. For example, if you have replaced your existing transmitter.
- If you were instructed by Customer Support to re-link your sensor.
SN: Transmitter Serial Number
LBL: Artwork part number
FCC ID:FCC is a US agency that regulates
certain device communications
The glucose data is stored in the cloud, not on your mobile device. If you are downloading the App onto a new device, the following data will automatically become available:
- Last 3 hours of glucose data
- Last 20 events
- Last 20 glucose alerts
The Eversense® E3 CGM System measures glucose in interstitial fluid (ISF) between the body’s cells.Physiologic differences between ISF and blood from a finger stick may result in differences in glucose measurements. These differences are especially evident during times of rapid change in blood glucose (e.g., after eating, dosing insulin, or exercising). On average, glucose levels in ISF lag behind glucose levels in blood by several minutes.
The trend arrow on the My Glucose screen of the Eversense® App screen will give you an indication of which direction the glucose is moving towards, up or down and the rate of change.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1